608 Results of a phase 1 study investigating camidanlumab tesirine as monotherapy and in combination with pembrolizumab in patients with selected advanced solid tumors

608 Results of a phase 1 study investigating camidanlumab tesirine as monotherapy and in combination with pembrolizumab in patients with selected advanced solid tumors

Bibliographische Detailangaben
Hauptverfasser:	Igor Puzanov, Shivaani Kummar, Sylvie Rottey, Patricia LoRusso, Kyriakos P Papadopoulos, Erika Hamilton, Josef Rüschoff, Fiona C Thistlethwaite, Nuria Kotecki, Christopher T Chen, Yvan LeBruchec, Jerzy Dyczkowski, Sara Samari, Marie Toukam, Joseph Boni, Karin Havenith, Serafino Pantano
Format:	Artikel
Sprache:	English
Veröffentlicht:	BMJ Publishing Group 2023-11-01
Schriftenreihe:	Journal for ImmunoTherapy of Cancer

Ähnliche Einträge

Acute Interstitial Nephritis Triggered by a Novel Anti-CD25 Antibody-Drug Conjugate, Camidanlumab Tesirine
von: Nicholas L. Li, et al.
Veröffentlicht: (2022-03-01)

S201: CAMIDANLUMAB TESIRINE: UPDATED EFFICACY AND SAFETY IN AN OPEN-LABEL, MULTICENTER, PHASE 2 STUDY OF PATIENTS WITH RELAPSED OR REFRACTORY CLASSICAL HODGKIN LYMPHOMA (R/R CHL)
von: C. Carlo-Stella, et al.
Veröffentlicht: (2022-06-01)

In relapsed or refractory diffuse large B‐cell lymphoma, CD19 expression by immunohistochemistry alone is not a predictor of response to loncastuximab tesirine
von: Paolo F. Caimi, et al.
Veröffentlicht: (2024-02-01)

Vesiculobullous eruption with loncastuximab tesirine in a patient with relapsed follicular lymphoma
von: Riyad N.H. Seervai, MD, PhD, et al.
Veröffentlicht: (2024-11-01)

Effects of Rovalpituzumab Tesirine on Ventricular Repolarization in Patients With Small‐Cell Lung Cancer
von: Jonathan W. Goldman, et al.
Veröffentlicht: (2021-03-01)

Rovalpituzumab Tesirine: A Novel DLL3-Targeting Antibody–Drug Conjugate
von: Bilal H. Lashari, et al.
Veröffentlicht: (2018-09-01)

Increasing patient participation in oncology clinical trials
von: Jie Chen, et al.
Veröffentlicht: (2023-02-01)

Illuminating immunotherapy response via precision T cell-targeted PET imaging
von: Sarah E. Glazer, et al.
Veröffentlicht: (2024-07-01)

Loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma: a review of clinical data
von: Fateeha Furqan, et al.
Veröffentlicht: (2022-03-01)

AGW 608 - CORPORATE STRATEGY APRIL 1997.
von: PPP, Pusat Pengajian Pengurusan
Veröffentlicht: (1997)

AGW 608 - CORPORATE STRATEGY JUN 1995
von: PPP, Pusat Pengajian Pengurusan
Veröffentlicht: (1995)

AGW 608 - CORPORATE STRATEGY APRIL 1993.
von: PPP, Pusat Pengajian Pengurusan
Veröffentlicht: (1993)

A phase I/II study of rovalpituzumab tesirine in delta-like 3—expressing advanced solid tumors
von: Aaron S. Mansfield, et al.
Veröffentlicht: (2021-08-01)

Outcomes with loncastuximab tesirine following CAR T-cell therapy in patients with relapsed or refractory diffuse large B-cell lymphoma
von: Narendranath Epperla, et al.
Veröffentlicht: (2024-11-01)

Real‐world treatment of large B‐cell lymphoma with chimeric antigen receptor T‐cell therapy after loncastuximab tesirine
von: Mehdi Hamadani, et al.
Veröffentlicht: (2024-10-01)

Was there a volcanic eruption off Vietnam in AD 608?
von: Khoo, T.
Veröffentlicht: (1993)

AGW 608 - CORPORATE STRATEGY APRIL 1993.pdf
von: PPP, Pusat Pengajian Pengurusan
Veröffentlicht: (1993)

P6.08 CHARACTERIZATIONS OF THE ARTERIAL SYSTEM COMPARED
von: N. Westerhof, et al.
Veröffentlicht: (2009-12-01)

Targeting CD19-positive lymphomas with the antibody-drug conjugate loncastuximab tesirine: preclinical evidence as single agent and in combination therapy
von: Chiara Tarantelli, et al.
Veröffentlicht: (2024-05-01)

Competing targets of microRNA-608 affect anxiety and hypertension
von: Geifman-Shochat, Susana, et al.
Veröffentlicht: (2014)

The Anticancer Effect of Napabucasin (BBI608), a Natural Naphthoquinone
von: Zeyang Shao, et al.
Veröffentlicht: (2023-07-01)

Biological Functions and Molecular Mechanisms of MiR-608 in Cancer
von: Juan Lu, et al.
Veröffentlicht: (2022-03-01)

MiR-608 overexpression in idiopathic pulmonary fibrosis (IPF)
von: Gali Epstein Shochet, et al.
Veröffentlicht: (2021-01-01)

EEG functional connectivity is sensitive for nitrogen narcosis at 608 kPa
von: Xavier C. E. Vrijdag, et al.
Veröffentlicht: (2022-03-01)

Cytogenetic Studies of 608 couples with Recurrent Spontaneous Abortions in Northeastern Iran
von: Narjes Soltani, et al.
Veröffentlicht: (2021-07-01)

Loncastuximab tesirine in relapsed/refractory diffuse large B-cell lymphoma: long-term efficacy and safety from the phase II LOTIS-2 study
von: Paolo F. Caimi, et al.
Veröffentlicht: (2023-08-01)

Characterization of the craniofacial abnormalities of the homozygous G608G progeria mouse model
von: Indeevar Beeram, et al.
Veröffentlicht: (2024-11-01)

A record of the transport of stone blocks on ostrakon DeB/F.608
von: Miroslaw Barwik
Veröffentlicht: (2019-12-01)

Economic Primer & Policy Analysis: Rent Control Policies & Oregon SB-608
von: Gabrielle A Brown
Veröffentlicht: (2021-05-01)

rs4919510 in hsa-mir-608 is associated with outcome but not risk of colorectal cancer.
von: Bríd M Ryan, et al.
Veröffentlicht: (2012-01-01)

Loncastuximab tesirine in Chinese patients with relapsed or refractory diffuse large B-cell lymphoma: a multicenter, open-label, single-arm, phase II trial
von: Ningjing Lin, et al.
Veröffentlicht: (2024-09-01)

PB2119: LONG-TERM SURVIVAL PROJECTIONS OF LONCASTUXIMAB TESIRINE-TREATED PATIENTS IN RELAPSED OR REFRACTORY (R/R) DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL)
von: M. Hamadani, et al.
Veröffentlicht: (2022-06-01)

PB2118: PHASE 3 RANDOMIZED STUDY OF LONCASTUXIMAB TESIRINE IN COMBINATION WITH RITUXIMAB (LONCA-R) VERSUS IMMUNOCHEMOTHERAPY IN PATIENTS WITH R/R DLBCL (LOTIS-5)
von: M. Hamadani, et al.
Veröffentlicht: (2022-06-01)

Postoperative Atrial Fibrillation Prophylaxis and Lung Resection – Our Experience with 608 Consecutive Patients
von: Vjekoslav Karadža, et al.
Veröffentlicht: (2017-01-01)

608 SARS-CoV-2 vaccine safety and side effects in people with SLE
von: Arielle Mendel, et al.
Veröffentlicht: (2022-12-01)

TIME-RESOLVED OPTICAL SPECTROSCOPY AND PHOTOMETRY OF THE PEOULIAR POLAR BY CAM (=H0538+608)
von: T. A. Somova, et al.
Veröffentlicht: (2017-06-01)

Les plantes génétiquement modifiées en Afrique : enjeux et recherches
von: De Lattre-Gasquet Marie, et al.
Veröffentlicht: (2002-11-01)

Laparoscopic mesh pectopexy for apical prolapse of the uterus or vagina: Interventional procedures guidance [IPG608]
von: National Institute for Clinical Health and Care Excellence, CA, et al.
Veröffentlicht: (2018)

Tactile/ electronic orientation devices for the visually handicapped : a selected bibiliography an update to A-608/
von: 346381 Preiser, Wolfgang F. E.
Veröffentlicht: (1983)

Causative drugs for drug-induced cutaneous reactions in central China: a 608-case analysis,
von: Jun Zhao, et al.
Veröffentlicht: (2020-02-01)